Introduction
============

Despite the existence of a comprehensive management strategy against breast cancer, both the incidence and the mortality rates of the disease are increasing. In the United States alone, 246,660 new breast cancer cases are expected in 2016, which account for 29% of all estimated new cancer diagnoses in females.[@b1-dddt-10-2359] Although the morbidity rate of breast cancer is lower in People's Republic of China compared with that in developed countries, since the 1990s, the incidence rate has been rising more than twice as fast as the worldwide average, resulting in its becoming the most common cancer in Chinese females.[@b2-dddt-10-2359] As is also the case for other malignancies, the development and progression of breast cancer comprise a complex process where genetic predisposition, environment, and lifestyle all play a role.[@b3-dddt-10-2359] For the past few years, the study of single nucleotide polymorphisms (SNPs) has been a focus area of oncological research into genetic factors, with respect to susceptibility, diagnosis, treatment, and prognosis of malignant tumors. Recent genome-wide association and large-scale replication studies have identified common variants in more than 70 loci associated with breast cancer.[@b4-dddt-10-2359]

Apoptosis, or programmed cell death, is a vital physiological process subjected to gene regulation. Aberrant regulation of apoptosis contributes to the development and progression, but also the treatment, of multiple diseases, including cancer.[@b5-dddt-10-2359],[@b6-dddt-10-2359] Fas, a cell surface protein also known as TNFSF6/CD95/APO-1, and Fas Ligand (*FasL*), a type II membrane protein, belong to the tumor necrosis factor receptor superfamily[@b7-dddt-10-2359],[@b8-dddt-10-2359] and play an important role in regulating apoptosis, as their crosslinking initiates the signal cascade of programmed cell death.[@b7-dddt-10-2359] Therefore, mutation in the *Fas* and *FasL* genes may affect the apoptotic procedure and, thus, the development and progression of tumors. Several pharmacogenetic studies revealed the association of *Fas/FasL* SNPs with the response of cancer chemotherapy, showing mutation of *Fas/FasL* may be an indicator of cancer treatment.[@b9-dddt-10-2359],[@b10-dddt-10-2359]

A large number of studies revealed that *Fas/FasL* gene polymorphisms are associated with susceptibility to various types of cancer, including cervical,[@b11-dddt-10-2359]--[@b14-dddt-10-2359] pharyngeal,[@b15-dddt-10-2359]--[@b17-dddt-10-2359] digestive,[@b18-dddt-10-2359]--[@b22-dddt-10-2359] and breast cancer.[@b23-dddt-10-2359]--[@b28-dddt-10-2359] Further studies demonstrated that circulating, soluble *Fas* (s*Fas*) can inhibit *Fas*-mediated apoptosis by neutralizing the *FasL* or the anti-*Fas* antibodies,[@b29-dddt-10-2359] while increased levels of s*Fas* have been observed in serum from patients with breast cancer.[@b30-dddt-10-2359] The most extensively investigated *Fas/FasL* polymorphisms are rs1800682 (−670A\>G) in the promoter region of *Fas* and rs763110 (−844C\>T) in the promoter region of *FasL*. However, the association of *Fas* and *FasL* gene polymorphisms with breast cancer has not been irrefutably established as different studies often produce conflicting results. For example, the study performed by Xu et al[@b28-dddt-10-2359] showed that the *Fas* rs1800682 and *FasL* rs763110 polymorphisms may reduce the risk of breast cancer, whereas Hashemi et al[@b27-dddt-10-2359] reported that the same SNPs were significantly associated with an increased risk of breast cancer (odds ratio, OR =3.18, *P*=0.019; OR =2.40, *P*=0.024, respectively), while Crew et al[@b23-dddt-10-2359] found no significant association between these two genetic polymorphisms and breast cancer risk. Thus, this case--control study was conducted to explore the role of these two polymorphisms (*Fas* rs1800682 and *FasL* rs763110) in breast cancer risk, in a Chinese population.

Materials and methods
=====================

Study population
----------------

Patients who had breast cancer and were being treated at the Department of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, were enrolled from January 2013 to October 2014. All the cases were verified using pathology and detailed immunohistochemical analysis, as described in our previous studies.[@b31-dddt-10-2359]--[@b33-dddt-10-2359] Patients with prior cancers or lacking a detailed personal and clinical background were excluded. Ultimately, 560 breast cancer cases were enrolled in this study; 583 healthy individuals who, during the same period, had gone for a checkup to the medical examination center of the same hospital, were included as controls. All the subjects in this study were Han Chinese females, and the controls were matched according to age (±5 years) and menopausal status.

Ethics statement
----------------

The study was approved by the Human Research Committee of Xi'an Jiaotong University. The demographic and personal information of patients and controls was collected using standard epidemiological questionnaires. Clinical information was collected from the patients' medical and pathological reports. All the participants were informed of the purpose and the experimental procedures of this study, and each subject signed a consent form.

Genotyping assay
----------------

Peripheral blood samples were collected in ethylenediaminetetraacetic acid (EDTA)-coated tubes and were preserved at −80°C.[@b31-dddt-10-2359] Genomic DNA was extracted from whole blood samples using the Universal Genomic DNA Extraction Kit (version 3.0; TaKaRa Bio Inc., Kusatsu, Japan) according to the manufacturer's instructions. DNA concentration was determined using the DU530 UV/VIS spectrophotometer (Beckman Instruments, Fullerton, CA, USA).[@b32-dddt-10-2359],[@b33-dddt-10-2359] Data from the HapMap database were used to create a list of potentially functional *Fas* and *FasL* SNPs discovered in Chinese subjects. Only SNPs with a minor allele frequency of \>0.01 were considered, in order to ensure a statistical power of at least 50%. In the end, two SNPs were chosen to be included in this study, *Fas* rs1800682 and *FasL*. A multiplexed SNP MassEXTEND assay was designed using the MassARRAY Assay Design 3.0 Software (Agena Bioscience, San Diego, CA, USA). All the SNPs were genotyped by the Sequenom MassARRAY RS1000 system (Agena Bioscience), according to the manufacturer's instructions. The primers used for the two SNPs are listed in [Table 1](#t1-dddt-10-2359){ref-type="table"}. Data were analyzed using the Typer 3.0 Software (Agena Bioscience).

Statistical analysis
--------------------

We used Microsoft Excel for data management and SPSS software (version 21.0, IBM Corporation, Armonk, NY, USA) for statistical analysis. Hardy--Weinberg equilibrium was examined using Fisher's exact test. Two-tailed Pearson's chi-square tests were used to evaluate the differences in allelic frequencies for each SNP between patients and controls, with *P*-values \<0.05 considered statistically significant. Five different genetic models were used to evaluate the association between SNPs and breast cancer risk ("A" and "a" are used to symbolize the major and the minor alleles, respectively): the allele model (a vs A); the codominant model (homozygote model: aa vs AA; heterozygote model: Aa vs AA); the recessive model (aa vs AA+Aa); the dominant model (AA vs Aa+aa); and the overdominant model (AA+aa vs Aa). SPSS software was used to estimate ORs and 95% confidence intervals (CIs) for each model. Stratification analysis was used to adjust for possible cofounders. Power and Sample Size (PS) Calculation software (<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize>) was used to calculate the power of the significant difference.[@b34-dddt-10-2359] Haplotype analysis was performed using PHASE v 2.1 software, while ORs and 95% CIs for all the haplotypes were determined using SPSS.[@b35-dddt-10-2359],[@b36-dddt-10-2359]

Results
=======

Characteristics of patients and controls
----------------------------------------

As shown in [Table 2](#t2-dddt-10-2359){ref-type="table"}, a total of 1,143 subjects (560 cancer cases and 583 healthy controls) were included in this study. Sporadic breast cancer patients were recruited from the Department of Oncology of The Second Affiliated Hospital of Xi'an Jiaotong University. Their average age was 49.09±11.02 years, and the diagnosis was confirmed by the examination of the pathology of surgical specimens. The controls we recruited were matched according to age and menopausal status. As a result, there was no significant difference between cases and controls with regard to general characteristics (*P*\>0.05). However, patients and controls significantly differed in the body mass index (kg/m^2^) value (*P*=0.038), which indicates that body mass index may be a confounding variable. Therefore, all the results were adjusted to body mass index.

Associations between *Fas/FasL* SNPs and the risk of breast cancer
------------------------------------------------------------------

The genotype frequency distribution of *Fas* rs1800682 and *FasL* rs763110 is shown in [Table 3](#t3-dddt-10-2359){ref-type="table"}. The genotype distributions in the control group were all in Hardy--Weinberg equilibrium (*P*-values of 0.163 and 0.817, respectively). Further analysis showed that significant differences exist among rs1800682 and rs763110 alleles with respect to breast cancer risk. The *Fas* rs1800682 G allele associated with high risk of breast cancer in the heterozygote, dominant, and overdominant models (AG vs AA: OR =1.37, 95% CI =1.06--1.78, *P*=0.015; AG+GG vs AA: OR =1.32, 95% CI =1.03--1.68, *P*=0.027; AA+AG vs GG: OR =1.32, 95% CI =1.04--1.66, *P*=0.021), with power values of 0.964, 0.856, and 0.910, respectively. In contrast, the rs763110 polymorphism associated with reduced risk of breast cancer (homozygote model: OR =0.63, 95% CI =0.40--0.98, *P*=0.040; dominant model: OR =0.76, 95% CI =0.60--0.96, *P*=0.022; allele model: OR =0.79, 95% CI =0.66--0.95, *P*=0.013). Moreover, power calculations confirm that the sample size was large enough to discover the differences among cases and controls in rs763110 (power =0.834, 0.906, and 0.719, respectively).

Stratification analysis of the association of *Fas/FasL* SNPs with breast cancer risk by age and menopausal status
------------------------------------------------------------------------------------------------------------------

The subgroup analyses were conducted in order to reveal the influence of age and menopausal status on breast cancer risk. A stratified analysis by age revealed significant associations between the two SNPs and the risk of breast cancer in females \>49 years of age in the allele model (rs1800682: OR =1.29, 95% CI =1.01--1.66, *P*=0.041; rs763110: OR =0.76, 95% CI =0.59--0.99, *P*=0.040) ([Table 4](#t4-dddt-10-2359){ref-type="table"}). Subgroup analyses by menopausal status found no association between rs1800682 and breast cancer risk in any genetic model (all, *P*\>0.05) ([Table 5](#t5-dddt-10-2359){ref-type="table"}). However, it was discovered that the rs763110 polymorphism was associated with lower breast cancer risk among postmenopausal females (heterozygote model: OR =0.69, 95%CI =0.49--0.97, *P*=0.030; dominant model: OR =0.70, 95%CI =0.51--0.96, *P*=0.028).

Associations between *Fas/FasL* SNPs and the clinicopathological features of breast cancer
------------------------------------------------------------------------------------------

We also explored the association between the two SNPs and the clinicopathological features of breast cancer, namely tumor size, lymph node metastasis, and the expression of the estrogen receptor, the progesterone receptor, the human epidermal growth factor receptor 2 (HER2) and Ki67. No associations were found between rs1800682 and breast cancer risk with respect to any of the aforementioned clinicopathological features, as in all the cases *P*-values were \>0.05 ([Table 6](#t6-dddt-10-2359){ref-type="table"}). In contrast, it was found that the T allele of rs763110 was associated with a decrease in the incidence of lymph node metastasis among breast cancer patients (allele model: OR =0.75, 95% CI =0.57--0.97, *P*=0.031), and higher incidence of the HER2-positive type of breast cancer among patients (allele model: OR =1.37, 95% CI =1.03--1.18, *P*=0.028) ([Table 6](#t6-dddt-10-2359){ref-type="table"}).

Association between *Fas/FasL* haplotypes and breast cancer risk
----------------------------------------------------------------

Haplotype analysis was conducted to evaluate the interaction of these two genes. As shown in [Table 7](#t7-dddt-10-2359){ref-type="table"}, it was found that the haplotype A~rs1800682~T~rs763110~ was significantly associated with a lower risk of breast cancer (OR =0.70, 95% CI =0.53--0.91, *P*=0.009). However, no relation was found between the other two haplotypes (G~rs1800682~C~rs763110~ and G~rs1800682~T~rs763110~) and breast cancer risk.

Discussion
==========

Apoptosis plays an important role in the genesis and development of tumors. The *Fas/FasL* genes are key effectors in the regulation of apoptotic cell death, and malfunction of this system has been proved to be important in cancer cell immune evasion and tumorigenesis.[@b37-dddt-10-2359] Decreased expression of *Fas* promotes malignant transformation and progression, while lower levels of *FasL* expression have the opposite effect.[@b38-dddt-10-2359]--[@b40-dddt-10-2359] Moreover, SNPs of the *Fas/FasL* genes were reported to be associated with many types of cancer susceptibility. However, the conclusions of these studies were inconsistent and the detailed subgroup analyses were limited. This case--control study including 560 breast cancer cases and 583 controls in Han Chinese females was performed in the hope of providing further evidence regarding the association between *Fas/FasL* SNPs and cancer risk.

The *Fas* rs1800682 polymorphism is located in a STAT1 binding element on the *Fas* promoter, which has been linked to the downregulation of Fas expression.[@b22-dddt-10-2359] The *FasL* gene rs763110 polymorphism lies within a putative binding motif for the CAAT/enhancer-binding protein β-transcription factor.[@b41-dddt-10-2359] Our results suggest that the *Fas* rs1800682 SNP may be associated with an increased risk of breast cancer, while the *FasL* rs763110 polymorphism may decrease breast cancer risk. Furthermore, the associations between these two SNPs and age, menopausal status, and different clinical characteristics of breast cancer were evaluated. Statistically significant associations were found between the two SNPs and the risk of breast cancer in the allele model among patients \>49 years of age. Moreover, the rs763110 polymorphism was more likely to decrease breast cancer risk among postmenopausal females. In 2012, a study of the Tunisian population including 438 breast cancer cases and 332 controls found that rs763110 had a marginally significant association with lymph node-negative status (OR =0.53, *P*=0.06; OR =0.73, *P*=0.07, respectively).[@b25-dddt-10-2359] However, it is demonstrated that the C allele of the rs763110 SNP may be associated with a lower risk of lymph node metastasis and a higher occurrence of HER2-positive breast cancers. The hormonal status is important to breast cancer patients, guiding treatment and prognosis. It has been demonstrated that upregulation of *Fas* and *FasL* in breast cancer cells induces T-cell apoptosis in Fas bearing T cells.[@b42-dddt-10-2359] However, we did not find any associations between *Fas/FasL* SNPs and hormone-related factors, which is in agreement with the data presented by Crew et al.[@b23-dddt-10-2359] Haplotypes are considered more meaningful than any SNP analysis during the genetic study. Xu et al[@b28-dddt-10-2359] reported that the G~rs2234767~A~rs1800682~ haplotype was associated with an increased breast cancer risk as compared with other haplotypes, whereas the A~rs2234767~A~rs1800682~ haplotype was associated with a reduced breast cancer risk. However, they did not evaluate the interaction of the *Fas* and *FasL* genes. The present study demonstrated that A~rs1800682~T~rs763110~ was significantly associated with low risk of breast cancer in comparison with A~rs1800682~C~rs763110~. Compared with the previous reports of breast cancer, this study offered more detailed information on these two SNPs and clinical characteristics of breast cancer, which may provide insights into the associations between *Fas/FasL* polymorphisms and the occurrence and development of breast cancer. Functional studies revealed that rs2234767 and rs1800682 polymorphisms were able to alter the SP1 and STAT1 binding site, leading to the abnormal expression of *Fas*,[@b43-dddt-10-2359] and C allele of rs763110 could increase basal *FasL* expression, affecting the *FasL*-mediated signaling.[@b41-dddt-10-2359] It was found that rs1800682 SNP had a high risk of breast cancer, and the mutation of rs763110 C allele may decrease the breast cancer risk. Thus, it was supposed that G allele of rs1800682 may downregulate *Fas* transcription via SP1/STAT1 way and the mutation of rs763110 may decrease the *FasL* expression by regulating *FasL*-mediated apoptotic signaling. However, the mechanisms still need more functional studies to testify.

Limitations
===========

The study had certain limitations: First, all the subjects were recruited from the same hospital, and therefore, selection bias is inevitable. Second, the sample size was not large enough to support the stratified analyses. Third, the effects of other important risk factors, such as polycyclic aromatic hydrocarbons, exposure of the chest area to high-dose radiation, and alcohol consumption, as well as benign breast lesions or environmental exposures, were not analyzed because of lack of relative data. Fourth, most patients included in this study were invasive ductal carcinoma cases; hence, stratification analyses were not performed for histopathological types of breast cancers. Fifth, only the differences of gene distribution in the subjects were analyzed. Functional studies are needed to reveal the molecular mechanism. Thus, a study with more patients and controls, containing both gene distribution and functional data, would allow us to both confirm and mechanistically interpret the results presented in the current study.

Conclusion
==========

In conclusion, this case--control study indicates that the *Fas* rs1800683 SNP is associated with a statistically significant degree of increased breast cancer risk, especially in females \>49 years of age. Conversely, the *FasL* rs763110 polymorphism was shown to be associated with decreased risk of breast cancer, especially in females \>49 years of age and after menopause. Moreover, stratified analyses demonstrated that the *FasL* rs763110 SNP was related to reducing the incidence of lymph node metastasis and increased chance for the breast cancer to be HER2-positive. Furthermore, the A~rs1800682~T~rs763110~ haplotype may play a protective role against breast cancer.
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###### 

Primers used for this study

  SNP_ID      First-PCRP                       Second-PCRP                      UEP-SEQ
  ----------- -------------------------------- -------------------------------- ------------------------
  rs1800682   ACGTTGGATGTTGTGGCTGCAACATGAGAG   ACGTTGGATGCTTTTCAGAGCCCTATGGCG   tGTTAACTGTCCATTCCAG
  rs763110    ACGTTGGATGCTGGGCAAACAATGAAAATG   ACGTTGGATGAGGCTGCAAACCAGTGGAAC   tcaaAGAGCTGCTTTGTATTTC

**Abbreviations:** PCRP, polymerase chain reaction primer; SNP, single nucleotide polymorphism; UEP-SEQ, unextension primer sequence.

###### 

The characteristics of breast cancer cases and cancer-free controls

  Characteristics                         Cases         Controls     *P*-value
  --------------------------------------- ------------- ------------ -----------
  Number                                  560           583          
  Age (years, mean ± SD)                  49.09±11.02   48.80±8.28   0.612
   \<49                                   294           311          
   ≥49                                    266           272          
  Menopausal status                                                  
   Premenopausal                          264           281          
   Postmenopausal                         296           302          0.716
  Number of pregnancies and live births                              
   \<2                                    289           291          0.594
   ≥2                                     271           292          
  Body mass index (kg/m^2^) (mean ± SD)   22.52±2.84    22.95±3.21   **0.038**
  Tumor size                                                         
   \<2 cm                                 188                        
   ≥2 cm                                  372                        
  LN metastasis                                                      
   Negative                               236                        
   Positive                               324                        
  ER                                                                 
   Negative                               247                        
   Positive                               313                        
  PR                                                                 
   Negative                               255                        
   Positive                               305                        
  HER2                                                               
   Negative                               389                        
   Positive                               171                        
  Ki67                                                               
   \<14%                                  195                        
   ≥14%                                   365                        

**Note:** The bold value indicates that the difference was significant.

**Abbreviations:** ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node; PR, progesterone receptor; SD, standard deviation.

###### 

Genotype frequencies of *Fas/FasL* polymorphisms in cases and controls

  Model                 Genotype                 Cases (n, %)   Controls (n, %)   *P*-value[\*](#tfn4-dddt-10-2359){ref-type="table-fn"}   OR (95% CI)             Study power
  --------------------- ------------------------ -------------- ----------------- -------------------------------------------------------- ----------------------- -------------
  ***Fas* rs1800682**   **HWE: *P***=**0.163**                                                                                                                     
  **Codominant**        AA                       182 (32.5)     226 (38.8)        1.00                                                                             
  Heterozygote          AG                       289 (51.6)     261 (44.8)        **0.015**                                                **1.37 (1.06--1.78)**   **0.964**
  Homozygote            GG                       89 (15.9)      96 (16.4)         0.428                                                    1.15 (0.81--1.63)       
  **Dominant**          AA                       226 (38.8)     182 (32.5)        1.00                                                                             
                        AG+GG                    357 (61.2)     378 (67.5)        **0.027**                                                **1.32 (1.03--1.68)**   **0.856**
  **Recessive**         AA+AG                    487 (83.6)     471 (84.1)        1.00                                                                             
                        GG                       96 (16.4)      89 (15.9)         0.792                                                    0.96 (0.70--1.31)       
  **Overdominant**      AA+GG                    322 (55.2)     271 (48.4)        1.00                                                                             
                        AG                       261 (44.8)     289 (51.6)        **0.021**                                                **1.32 (1.04--1.66)**   **0.910**
  **Allele**            A                        713 (61.1)     653 (58.3)        1.00                                                                             
                        G                        453 (38.9)     467 (41.7)        0.165                                                    1.13 (0.95--1.33)       
  ***FasL* rs763110**   **HWE: *P***=**0.817**                                                                                                                     
  **Codominant**        CC                       303 (54.1)     276 (47.3)        1.00                                                                             
  Heterozygote          CT                       219 (39.1)     252 (43.2)        0.060                                                    0.79 (0.62--1.01)       
  Homozygote            TT                       38 (6.8)       55 (9.5)          **0.040**                                                **0.63 (0.40--0.98)**   **0.834**
  **Dominant**          CC                       303 (54.1)     276 (47.3)        1.00                                                                             
                        CT+TT                    257 (45.9)     307 (52.7)        **0.022**                                                **0.76 (0.60--0.96)**   **0.906**
  **Recessive**         CC+CT                    522 (93.2)     528 (90.5)        1.00                                                                             
                        TT                       38 (6.8)       55 (9.5)          0.102                                                    0.70 (0.45--1.08)       
  **Overdominant**      CC+TT                    341 (60.9)     331 (56.8)        1.00                                                                             
                        CT                       219 (39.1)     252 (43.2)        0.157                                                    0.84 (0.67--1.07)       
  **Allele**            C                        825 (73.7)     804 (69.0)        1.00                                                                             
                        T                        295 (26.3)     362 (31.0)        **0.013**                                                **0.79 (0.66--0.95)**   **0.719**

**Notes:**

Adjusted for age and body mass index. The bold values indicate that the differences were significant.

**Abbreviations:** CI, confidence interval; HWE, Hardy--Weinberg equilibrium; OR, odds ratio.

###### 

Association between *Fas*/*FasL* SNPs and age of breast cancer patients

  Age (years)   (AA/Aa/aa)      Codominant   Dominant                                            Recessive                                                       Allele                                                               
  ------------- --------------- ------------ --------------------------------------------------- --------------------------------------------------------------- -------- ------------------- ------- ------------------- ----------- -----------------------
                **rs1800682**                                                                                                                                                                                                         
  \<49          81/166/47       101/156/54   0.128[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   1.33 (0.92--1.91)[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   0.187    1.27 (0.89--1.79)   0.650   0.91 (0.59--1.39)   0.534       1.08 (0.86--1.35)
                                             0.742[n](#tfn8-dddt-10-2359){ref-type="table-fn"}   1.09 (0.67--1.77)[n](#tfn8-dddt-10-2359){ref-type="table-fn"}                                                                        
  ≥49           101/113/52      125/105/42   0.132[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   1.33 (0.92--1.94)[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   0.061    1.39 (0.99--1.96)   0.210   1.33 (0.85--2.08)   **0.041**   **1.29 (1.01--1.66)**
                                             0.083[n](#tfn8-dddt-10-2359){ref-type="table-fn"}   1.53 (0.95--2.49)[n](#tfn8-dddt-10-2359){ref-type="table-fn"}                                                                        
                **rs763110**                                                                                                                                                                                                          
  \<49          169/106/19      161/124/26   0.233[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   0.81 (0.58--1.14)[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   0.158    0.79 (0.58--1.09)   0.374   0.76 (0.41--1.40)   0.134       0.82 (0.64--1.06)
                                             0.258[n](#tfn8-dddt-10-2359){ref-type="table-fn"}   0.70 (0.37--1.31)[n](#tfn8-dddt-10-2359){ref-type="table-fn"}                                                                        
  ≥49           134/113/19      115/128/29   0.125[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   0.76 (0.53--1.08)[m](#tfn7-dddt-10-2359){ref-type="table-fn"}   0.060    0.72 (0.51--1.04)   0.152   0.65 (0.35--1.18)   **0.040**   **0.76 (0.59--0.99)**
                                             0.071[n](#tfn8-dddt-10-2359){ref-type="table-fn"}   0.56 (0.30--1.06)[n](#tfn8-dddt-10-2359){ref-type="table-fn"}                                                                        

**Notes:** A represents major allele; a represents minor allele;

represents heterozygote model;

represents homozygote model. The bold values indicate that the differences were significant.

**Abbreviations:** CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.

###### 

Association between *Fas*/*FasL* SNPs and menopausal status of breast cancer patients

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Menopausal status   (AA/Aa/aa)      Codominant   Dominant                                                  Recessive                                                             Allele                                                        
  ------------------- --------------- ------------ --------------------------------------------------------- --------------------------------------------------------------------- ----------- ------------------ ------- -------------- ------- --------------
                      **rs1800682**                                                                                                                                                                                                              

  Premenopausal       87/128/49       114/121/46   0.086[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\       1.39 (0.9--2.01)[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\        0.066       1.39\              0.501   1.16\          0.099   1.23\
                                                   0.181[n](#tfn12-dddt-10-2359){ref-type="table-fn"}        1.40 (0.86--2.28)[n](#tfn12-dddt-10-2359){ref-type="table-fn"}                    (0.98--1.97)               (0.75--1.81)           (0.96--1.56)

  Postmenopausal      95/161/40       112/140/50   0.093[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\       1.36 (0.95--1.93)[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\       0.200       1.25\              0.298   0.79\          0.731   1.04\
                                                   0.818[n](#tfn12-dddt-10-2359){ref-type="table-fn"}        0.94 (0.57--1.55)[n](#tfn12-dddt-10-2359){ref-type="table-fn"}                    (0.89--1.75)               (0.50--1.24)           (0.83--1.31)

                      **rs763110**                                                                                                                                                                                                               

  Premenopausal       147/99/18       144/105/32   0.664[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\       0.92 (0.65--1.32)[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\       0.299       0.84\              0.065   0.57\          0.098   0.80\
                                                   0.058[n](#tfn12-dddt-10-2359){ref-type="table-fn"}        0.55 (0.30--1.03)[n](#tfn12-dddt-10-2359){ref-type="table-fn"}                    (0.60--1.17)               (0.31--1.04)           (0.61--1.04)

  Postmenopausal      156/120/20      132/147/23   **0.030**[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\   **0.69 (0.49--0.97)**[m](#tfn11-dddt-10-2359){ref-type="table-fn"}\   **0.028**   **0.70**\          0.684   0.88\          0.062   0.79\
                                                   0.348[n](#tfn12-dddt-10-2359){ref-type="table-fn"}        0.74 (0.39--1.40)[n](#tfn12-dddt-10-2359){ref-type="table-fn"}                    **(0.51--0.96)**           (0.47--1.64)           (0.62--1.01)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** A represents major allele; a represents minor allele;

represents heterozygote model;

represents homozygote model. The bold values indicate that the differences were significant.

**Abbreviations:** CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.

###### 

Association between the *Fas*/*FasL* SNPs and clinical characteristics of breast cancer patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables       AA    Aa    aa   Codominant                                                                                              Dominant                                                          Recessive   Allele                                                      
  --------------- ----- ----- ---- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------- ------------------- ------- ------------------- ----------- -----------------------
  **rs1800682**                                                                                                                                                                                                                                                                      

  Tumor size                                                                                                                                                                                                                                                                         

   \<2 cm         67    96    25   1.00 (reference)                                                                                                                                                                                                                                  

   ≥2 cm          115   193   64   0.425[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.17 (0.79--1.73)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.218       0.26 (0.87--1.83)   0.232   1.36 (0.82--2.23)   0.167       1.20 (0.93--1.54)
                                   0.154[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      1.49 (0.86--2.59)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  LN metastasis                                                                                                                                                                                                                                                                      

   Negative       84    121   31   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       98    168   58   0.361[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.19 (0.82--1.73)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.182       1.27 (0.89--1.82)   0.128   1.44 (0.90--2.31)   0.090       1.23 (0.97--1.57)
                                   0.077[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      1.60 (0.95--2.71)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  ER                                                                                                                                                                                                                                                                                 

   Negative       90    119   38   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       92    170   51   0.078[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.40 (0.96--2.03)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.077       1.38 (0.97--1.97)   0.770   1.07 (0.68--1.69)   0.180       1.18 (0.93--1.50)
                                   0.296[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      1.31 (0.79--2.19)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  PR                                                                                                                                                                                                                                                                                 

   Negative       89    122   44   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       93    167   45   0.155[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.31 (0.90--1.90)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.267       1.22 (0.86--1.74)   0.420   0.83 (0.53--1.31)   0.747       1.04 (0.82--1.32)
                                   0.934[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      0.98 (0.59--1.63)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  HER2                                                                                                                                                                                                                                                                               

   Negative       134   193   62   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       48    96    27   0.116[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.39 (0.92--2.09)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.138       1.35 (0.91--2.00)   0.965   0.99 (0.60--1.62)   0.330       1.14 (0.88--1.47)
                                   0.493[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      1.22 (0.70--2.13)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  KI67                                                                                                                                                                                                                                                                               

   \<14%          61    108   26   1.00 (reference)                                                                                                                                                                                                                                  

   ≥14%           121   181   63   0.396[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     0.85 (0.57--1.25)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.653       0.92 (0.63--1.33)   0.226   1.36 (0.83--2.22)   0.739       1.04 (0.81--1.34)
                                   0.476[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      1.22 (0.70--2.12)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  **rs763110**                                                                                                                                                                                                                                                                       

  Tumor size                                                                                                                                                                                                                                                                         

   \<2 cm         98    79    11   1.00 (reference)                                                                                                                                                                                                                                  

   ≥2 cm          205   140   27   0.374[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     0.85 (0.59--1.22)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.504       0.89 (0.62--1.26)   0.532   1.26 (0.61--2.60)   0.778       0.96 (0.73--1.27)
                                   0.672[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      1.17 (0.56--2.46)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  LN metastasis                                                                                                                                                                                                                                                                      

   Negative       117   98    21   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       186   121   17   0.160[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     0.78 (0.55--1.11)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.066       0.73 (0.52--1.02)   0.090   0.57 (0.29--1.10)   **0.031**   **0.75 (0.57--0.97)**
                                   0.049[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      0.51 (0.26--1.01)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  ER                                                                                                                                                                                                                                                                                 

   Negative       121   109   17   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       182   200   21   0.234[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.22 (0.88--1.69)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.342       1.17 (0.85--1.60)   0.378   0.74 (0.38--1.44)   0.680       1.05 (0.82--1.35)
                                   0.570[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      0.82 (0.42--1.62)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  PR                                                                                                                                                                                                                                                                                 

   Negative       144   88    23   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       159   131   15   0.096[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.35 (0.95--1.92)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.305       1.19 (0.85--1.66)   0.055   0.52 (0.27--1.02)   0.964       1.01 (0.77--1.31)
                                   0.131[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      0.59 (0.30--1.18)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  HER2                                                                                                                                                                                                                                                                               

   Negative       221   146   22   1.00 (reference)                                                                                                                                                                                                                                  

   Positive       82    73    16   0.122[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\                                                     1.35 (0.92--1.97)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.053       1.43 (1.00--2.05)   0.109   1.72 (0.88--3.37)   **0.028**   **1.37 (1.03--1.18)**
                                   0.053[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                      1.43 (1.00--2.05)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            

  KI67                                                                                                                                                                                                                                                                               

   \<14%          103   74    18   1.00 (reference)                                                                                                                                                                                                                                  

   ≥14%           200   145   20   0.961[m](#tfn15-dddt-10-2359){ref-type="table-fn"} 0.104[n](#tfn16-dddt-10-2359){ref-type="table-fn"}   1.01 (0.70--1.46)[m](#tfn15-dddt-10-2359){ref-type="table-fn"}\   0.655       0.92 (0.65--1.31)   0.975   1.01 (0.72--1.40)   0.300       0.86 (0.66--1.14)
                                                                                                                                           0.57 (0.29--1.13)[n](#tfn16-dddt-10-2359){ref-type="table-fn"}                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** A represents major allele; a represents minor allele;

represents heterozygote model;

represents homozygote model. The bold values indicate that the differences were significant.

**Abbreviations:** CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node; OR, odds ratio; PR, progesterone receptor; SNP, single nucleotide polymorphism.

###### 

The haplotype frequencies of *Fas/FasL* SNPs and breast cancer risk

  Haplotypes   Cases (N=1,120) n, %   Controls (N=1,166) n, %   OR (95% CI)   *P*-value               
  ------------ ---------------------- ------------------------- ------------- ----------------------- -----------
  A            C                      544 (48.57)               556 (47.68)   1.00 (reference)        
  A            T                      109 (9.73)                157 (13.46)   **0.70 (0.53--0.91)**   **0.009**
  G            C                      281 (25.09)               248 (21.27)   1.14 (0.92--1.40)       0.224
  G            T                      186 (16.61)               205 (17.58)   0.91 (0.72--1.15)       0.426

**Note:** The bold value indicates that the difference was significant.

**Abbreviations:** CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.
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